Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reagan-Udall, Still Waiting For FDA Funding, Studies Drug Toxicity Pathways

Executive Summary

Created by Congress to help FDA modernize medical product development and evaluation, the foundation will receive its first influx of federal money to support overhead in fiscal 2012.

Advertisement

Related Content

Post-Market Drug Surveillance Research Methods Are Focus Of Reagan-Udall Program
Increased FDA China Inspections Backed By House Panel, While Purse Strings Pulled Still Tighter
TB Regimen Could Pave Way For More FDA Involvement In Neglected Tropical Diseases
FDA Coffers Fill With Funds, But No Money For Reagan-Udall Or Lab Closures

Topics

Advertisement
UsernamePublicRestriction

Register

PS054346

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel